Safety evaluation of current therapies for high risk severely-ill patients with carbapenem-resistant infections

Expert Opin Drug Saf. 2021 Oct 9. doi: 10.1080/14740338.2022.1990262. Online ahead of print.ABSTRACTINTRODUCTION: Infections due to carbapenem resistant gram-negative bacteria (CR-GNB) are an increasingly frequent events, that are associated with high mortality rate. Traditionally, combination regimens including high doses of "old antibiotics" such as polymyxins, tigecycline and aminoglycosides have been used to treat these infections, but they were often associated with low efficacy and high excess of side effects and toxicity, especially nephrotoxicity. Along with the development of new compounds, the last decade has seen substantial improvements in the management of CR-infections.AREAS COVERED: In this review, we aimed to discuss the safety characteristics and tolerability of different new options for treatment of CR- infections.EXPERT OPINION: The availability of new drugs showing a potent in vitro activity against CR-GNB represents a unique opportunity to face the threat of resistance, while potentially reducing toxicity. A thorough understanding of the safety profile from clinical trials may guide the use of these new drugs in critically ill-patients at high risk for the development of adverse events. Future data coming from real-life studies for drugs targeting CR- infections are crucial to confirm the safety profile observed in pivotal trials.PMID:34632905 | DOI:10.1080/14740338.2022.1990262
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Authors: Source Type: research